Cipla
Drug Manufacturers - Specialty & Generic · CIPLA
Mega CapHealthcareMature Stable
Umang Vohra
Managing Director and Global CEO · Transformational
Company DNA
Performance-Driven
About
Cipla is a Mega Cap company in the Healthcare sector, listed on NSE as CIPLA. With a market cap of ₹107K Cr and revenue of ₹27K Cr, it is currently in the Mature Stable phase. Known for its Performance-Driven culture and Fast-Follower approach to innovation, the company operates at a Steady-Marathon pace. Professional management team focused on operational excellence and aggressive international market expansion. Its strategic mandate: The company needs to modernize its supply chain and patient engagement platforms to sustain its deep-rooted domestic market dominance against aggressive new-age competition.
FAQ
What kind of company is Cipla?
Cipla is a Mega Cap Healthcare company (CIPLA) in the Mature Stable phase with a market cap of ₹107K Cr. It is classified as Performance-Driven in culture.
What is Cipla's culture and work environment like?
Cipla has a Performance-Driven culture with Fast-Follower innovation DNA and a Steady-Marathon pace of execution. Employee brand: Learning Ground. Customer relationship style: B2B-Enterprise. Professional management team focused on operational excellence and aggressive international market expansion.
Who leads Cipla?
Cipla is led by Umang Vohra (Managing Director and Global CEO), a Transformational leader with 28 years of experience.
What are Cipla's financials?
Cipla reported revenue of ₹27K Cr in FY25 with a 5-year revenue CAGR of 7.9%. Operating margin: 22.6%. Market cap: ₹107K Cr.
Culture & Strategy
CulturePerformance-Driven
InnovationFast-Follower
PaceSteady-Marathon
PurposeMission-First
CustomerB2B-Enterprise
EmployeeLearning Ground
BrandTrusted
LifecycleMature Stable
Professional management team focused on operational excellence and aggressive international market expansion.
Mandate
The company needs to modernize its supply chain and patient engagement platforms to sustain its deep-rooted domestic market dominance against aggressive new-age competition.
The company needs to modernize its supply chain and patient engagement platforms to sustain its deep-rooted domestic market dominance against aggressive new-age competition.
Financials
Revenue FY25₹27K Cr
PAT FY25₹5K Cr
Rev CAGR 5Y7.9%
OPM22.6%
NPM19.4%
ROE16.9%
ROCE19.3%
P/E23.4
Fwd P/E23.5
P/B3.2
D/E1.4
Mkt Cap₹107K Cr
Promoter31%
Institutional42.6%
Similar Culture
Could You Lead Cipla?
Take the Genome Benchmark →